Redefining Clinical Response Criteria in Myelodysplastic Syndromes to Better Forecast Post-Transplant Outcomes
Luis E. Aguirre(Harvard University), Maximilian Stahl(Harvard University), Rami S. Komrokji(Moffitt Cancer Center), Kelly Ling(Dana-Farber Cancer Institute), Eric S. Winer(Providence College), Roman M. Shapiro(Boston University), Hany Elmariah(Moffitt Cancer Center), Marlise R. Luskin(Dana-Farber Cancer Institute), Corey Cutler(Harvard University), Mahasweta Gooptu(Harvard University), Haesook T. Kim(Dana-Farber Cancer Institute), Martha Wadleigh(Dana-Farber Cancer Institute), Vincent T. Ho, Shai Shimony(Twitter (United States)), Evan C. Chen(Dana-Farber Cancer Institute), Joseph H. Antin(Dana-Farber Cancer Institute), Stacey M. Frumm(Dana-Farber Cancer Institute), Benjamin Rolles(Brigham and Women's Hospital), Rizwan Romee(Washington University in St. Louis), Amar H. Kelkar(Harvard University), Robert J. Soiffer(Dana-Farber Cancer Institute), Richard M. Stone(Dana-Farber Cancer Institute), Daniel J. DeAngelo(Dana-Farber Cancer Institute), John Koreth, Jacqueline S. Garcia(Dana-Farber Cancer Institute), Najla H. Al Ali(Moffitt Cancer Center), Sarah Nikiforow(Otsuka (Japan))
Cited by 0
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
|New England Journal of Medicine|2020|1.4k